Format

Send to

Choose Destination
Neurology. 2015 Jan 6;84(1):57-63. doi: 10.1212/WNL.0000000000001098. Epub 2014 Nov 19.

CSF biomarkers and clinical progression of Parkinson disease.

Author information

1
From the Department of Neurology (S.H., Y.S.) and Memory Clinic (O.H.), Skåne University Hospital; Department of Clinical Sciences (S.H., Y.S., D.L., O.H.), Lund University; Department of Psychiatry and Neurochemistry (A.O., H.Z.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg and Mölndal, Sweden; UCL Institute of Neurology (H.Z.), Queen Square, London, UK; and Psychiatry Skåne (D.L.), Lund, Sweden. Sara.Hall@med.lu.se Oskar.Hansson@med.lu.se.
2
From the Department of Neurology (S.H., Y.S.) and Memory Clinic (O.H.), Skåne University Hospital; Department of Clinical Sciences (S.H., Y.S., D.L., O.H.), Lund University; Department of Psychiatry and Neurochemistry (A.O., H.Z.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg and Mölndal, Sweden; UCL Institute of Neurology (H.Z.), Queen Square, London, UK; and Psychiatry Skåne (D.L.), Lund, Sweden.

Abstract

OBJECTIVE:

To investigate whether certain CSF biomarkers at baseline can predict future progression of motor symptoms and cognitive decline in patients with Parkinson disease (PD).

METHODS:

Patients and controls were recruited from hospitals in southern Sweden as part of the prospective and longitudinal Swedish BioFinder Study. In the present study, we included 42 patients with PD and 69 controls who had clinical assessment and lumbar puncture at baseline. Baseline CSF samples were analyzed for α-synuclein (αSyn), β-amyloid 1-42 (Aβ42), tau, phosphorylated tau, and neurofilament light. Associations between CSF markers at baseline and change in clinical characteristics after 2 years of follow-up were investigated using multivariate models adjusting for age, sex, disease duration, and levodopa-equivalent daily dose.

RESULTS:

Higher levels of αSyn within the PD group were associated with progression of motor symptoms and cognitive decline over 2 years, indicated by significant relationships between αSyn and change in Hoehn and Yahr (β = 0.394, p = 0.043), Unified Parkinson's Disease Rating Scale, Part III (UPDRS-III) (β = 0.449, p = 0.013), Timed Up and Go (β = 0.406, p = 0.023), and A Quick Test of Cognitive Speed (β = 0.423, p = 0.018). Lower levels of Aβ42 were associated with worsening of performance on delayed memory recall (F = 5.834, p = 0.022). Finally, high levels of phosphorylated tau were associated with worsening in motor symptoms (UPDRS-III, β = 0.350, p = 0.045; Hoehn and Yahr, β = 0.366, p = 0.038).

CONCLUSION:

We found evidence of a link between higher levels of αSyn at baseline and worsening of motor symptoms and cognitive speed over 2 years in PD. Increased αSyn might be a marker of more intense synaptic degeneration in PD. The results indicate that cortical amyloid pathology (low CSF Aβ42) is associated with memory decline.

PMID:
25411441
PMCID:
PMC4336091
DOI:
10.1212/WNL.0000000000001098
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center